ALK plus NSCLC ALK Inhibitors symbolize Progress in Cancer Medicine

被引：0
|
作者：
Kohl, Angelika
机构：
来源：
ONCOLOGY RESEARCH AND TREATMENT | 2021年 / 44卷 / 7-8期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：435 / 435
页数：1
相关论文
共 50 条
  • [41] SHP2 inhibition restores sensitivity to ALK inhibitors in resistant ALK-rearranged NSCLC
    Dardaei, Leila
    Wang, Hui Qin
    Singh, Manrose
    Fordjour, Paul
    Yoda, Satoshi
    Kerr, Grainne
    Liang, Jinsheng
    Cao, Yichen
    Chen, Yan
    Gainor, Justin
    Friboulet, Luc
    Dagogo-Jack, Ibiayi
    Myers, David
    Labrot, Emma
    Ruddy, David
    Parks, Melissa
    Lee, Dana
    DiCecca, Richard
    Moody, Susan
    Hao, Huaixiang
    Mohseni, Morvarid
    LaMarche, Matthew
    Williams, Juliet
    Hoffmaster, Keith
    Caponigro, Giordano
    Shaw, Alice
    Hata, Aaron
    Benes, Cyril
    Li, Fang
    Engelman, Jeffrey
    MOLECULAR CANCER THERAPEUTICS, 2018, 17 (01)
  • [42] ALK INHIBITORS
    Blackhall, F.
    JOURNAL OF THORACIC ONCOLOGY, 2012, 7 (06) : S20 - S21
  • [43] ALK inhibitors and cranial radiotherapy in brain metastasis from NSCLC
    Cihan, Yasemin Benderli
    JOURNAL OF BUON, 2018, 23 (05): : 1558 - 1558
  • [44] Safety issues with the ALK inhibitors in the in the treatment of NSCLC: A systematic review
    Kassem, Loay
    Shohdy, Kyrillus S.
    Lasheen, Shaimaa
    Abdel-Rahman, Omar
    Ali, Ahmad
    Abdel-Malek, Raafat R.
    CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY, 2019, 134 : 56 - 64
  • [45] Precision medicine in ALK rearranged NSCLC: A rapidly evolving scenario
    Addeo, Alfredo
    Tabbo, Fabrizio
    Robinson, Tim
    Buffoni, Lucio
    Novello, Silvia
    CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY, 2018, 122 : 150 - 156
  • [46] A retrospective observational study to evaluate patient-reported outcomes (PROs) in patients with metastatic ALK plus non-small cell lung cancer (NSCLC) treated with ALK inhibitors
    Biber, Josh
    Wan, Yin
    Churchill, Eric N.
    Danes, Christopher G.
    Socinski, Mark A.
    Spira, Alexander I.
    JOURNAL OF THORACIC ONCOLOGY, 2024, 19 (07) : E36 - E36
  • [47] ALK inhibitors: a new targeted therapy in the treatment of advanced NSCLC
    Casaluce, Francesca
    Sgambato, Assunta
    Maione, Paolo
    Rossi, Antonio
    Ferrara, Carmine
    Napolitano, Alba
    Palazzolo, Giovanni
    Ciardiello, Fortunato
    Gridelli, Cesare
    TARGETED ONCOLOGY, 2013, 8 (01) : 55 - 67
  • [48] Effectiveness of ALK inhibitors in treatment of CNS metastases in NSCLC patients
    Gil, Michal
    Knetki-Wroblewska, Magdalena
    Nizinski, Przemyslaw
    Strzemski, Maciej
    Krawczyk, Pawel
    ANNALS OF MEDICINE, 2023, 55 (01) : 1018 - 1028
  • [49] ALK inhibitors: a new targeted therapy in the treatment of advanced NSCLC
    Francesca Casaluce
    Assunta Sgambato
    Paolo Maione
    Antonio Rossi
    Carmine Ferrara
    Alba Napolitano
    Giovanni Palazzolo
    Fortunato Ciardiello
    Cesare Gridelli
    Targeted Oncology, 2013, 8 : 55 - 67
  • [50] ALKTERNATE: A Pilot Study Alternating Lorlatinib with Crizotinib in Patients with ALK plus NSCLC and ALK-inhibitor Resistance
    Itchins, M.
    Liang, S.
    Brown, C.
    Barnes, T.
    Marx, G.
    Chin, V.
    Kao, S.
    Yip, P. Y.
    Mersiades, A. J.
    Nagrial, A.
    Bray, V.
    Peters, G.
    Parakh, S.
    John, T.
    Li, M.
    Li, B. T.
    McKay, M.
    Molloy, M.
    O'Byrne, K.
    Lee, C.
    Gill, A.
    Solomon, B. J.
    Pavlakis, N.
    JOURNAL OF THORACIC ONCOLOGY, 2023, 18 (11) : S351 - S352
12345